Medicinal Chemistry Journal of Medicinal Chemistry
Skipping the E3 ligase: degraders that dock on the proteasome
- This Perspective reviews degraders that tether targets straight to the proteasome, bypassing E3 ligases and ubiquitination and possibly widening the degradable proteome.
- It surveys ligands for the 19S regulatory particle and 20S core, and how different subunits and pockets have been used.
- Challenges split into ligand issues (unclear sites, immature SAR, uncertain linker exits) and degrader issues (exposure, selectivity, off-targets, proteostasis risk).
Swapping a CRBN or VHL handle for a proteasome binder only makes sense if the ligand is not an inhibitor in disguise. Many known 20S/19S ligands perturb catalytic activity, so a degrader needs a readout separating target loss from general proteostasis stress. And with so abundant a partner, it is unclear whether ternary-complex cooperativity matters as it does with E3s. Start with a non-binding-handle control and global proteomics.
Paper: Journal of Medicinal Chemistry ↗ From Ubiquitination to Proteasome-Directed Recruiting: Emerging Mechanisms and Therapeutic Potential in Targeted Protein Degradation